Part 11 draft guidance withdrawn
This article was originally published in The Gray Sheet
Executive Summary
FDA rescinds November draft guidance entitled "Guidance for Industry, 21 CFR Part 11; Electronic Records; Electronic Signatures, Electronic Copies of Electronic Records," in light of Good Manufacturing Practice initiative for drugs and biologics, announced in August (1"The Gray Sheet" Aug. 26, 2002, p. 3). "The agency wishes to limit the time spent by industry reviewing and commenting on the guidance, which may no longer represent FDA's approach under the cGMP initiative," FDA explains in Feb. 4 Federal Register notice. Comments would have been due Feb. 10 (2"The Gray Sheet" Nov. 18, 2002, p. 12)...
You may also be interested in...
FDA Eases Up On Part 11 Scope, Pulls Old Guidelines
FDA will scale back enforcement of its electronic records and signatures rule (Part 11) for all FDA-regulated products while it reassesses the regulation in light of the agency's current good manufacturing practice initiative for drugs and biologics
FDA News In Brief
Abbreviated 510(k) project update: The Centers for Devices & Radiological Health is looking to finish, in the first quarter of 2003, collaborations with several manufacturers to draft abbreviated 510(k) summary reports, staffers say. An invitation to work with CDRH to create example summary reports serving as templates was extended to abbreviated 510(k) sponsors by the device center in June (1"The Gray Sheet" June 3, 2002, p. 3). Although CDRH has had inquiries from a number of manufacturers, not all have been fruitful, according to staffers, who are still searching for additional manufacturers with whom to collaborate on the initiative. The project is open to devices with Class II special controls final guidance documents...
Combination Product Oversight Will Be Partly Affected By Drug GMP Initiative
FDA's initiative to enhance pharmaceutical good manufacturing practices will apply to combination products that have biological drug or drug components